Clinuvel Pharmaceuticals Limited balance sheet CLVLF
As of Jun 30, 2026, Clinuvel Pharmaceuticals Limited had total assets of $204.0 million and total liabilities of $15.4 million. Stockholders' equity was $188.6 million. It held $174.0 million in cash and investments against $1.3 million of total debt, net cash of $172.7 million. The current ratio, current assets divided by current liabilities, was 14.72.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
|---|---|
| Assets | |
| Cash |
14
|
| Short-term investments |
160
|
| Cash and investments |
174
|
| Receivables |
16
|
| Inventory |
5
|
| Total current assets |
197
|
| Property and equipment, net |
5
|
| Total assets |
204
|
| Liabilities and equity | |
| Total current liabilities |
13
|
| Total liabilities |
15
|
| Stockholders' equity |
189
|
| Debt | |
| Lease liabilities |
1
|
| Total debt |
1
|
| Net cash |
173
|
| Ratios | |
| Current ratio |
14.72x
|
| Debt to equity |
0.01x
|
| Debt to EBITDA |
0.05x
|
| Return on equity |
12.29%
|
| Return on assets |
11.36%
|
| Book value per share |
3.74
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.
Company profile
- Industry
- American Depositary Receipts (SIC 8880)
- Listed as
- CUVL (Nasdaq), CLVLF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Melbourne, Victoria
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1290877
- Former names
- EpiTan LTD (until Mar 20, 2006)
Other American Depositary Receipts companies
- Kongsberg Gruppen ASA/ADR KBGGY
- Sumitomo Electric Industries LTD/ADR/ SMTOY
- MTN Group LTD/ADR MTNOY
- Daiwa Securities Group Inc. DSEEY
- Yara International ASA YARIY
- Weir Group PLC/ADR WEGRY
- Pandora A/S / ADR PNDRY
- Vibra Energia S.A./ADR VBREY
Source: SEC EDGAR filings. This is company-reported data, not investment advice.